Retmarker now available in Europe

Article

Critical Health has announced that Retmarker, its software solution for decision support in the ophthalmology domain, attained the right to hold the CE 0197 branding, that classifies it as a Class IIa Medical Device at a European level.

Critical Health has announced that Retmarker, its software solution for decision support in the ophthalmology domain, attained the right to hold the CE 0197 branding, that classifies it as a Class IIa Medical Device at a European level. This certification enables the company to start commercializing this software tool, which allows for a detailed analysis, using non-invasive imaging methods, of several retinal pathologies.

Available in several versions, RetmarkerDR monitors the progression of diabetic retinopathy using advanced proprietary algorithms that help ophthalmologists detect and calculate the formation and disappearance rates of microaneurysms in the retina. This allows them to infer, with the help of this information, the evolution of a disease that is one of the fastest growing causes of preventable blindness in developed countries. RetmarkerC enables the detection of changes in the retina due to several pathologies. Finally RetmarkerAMD is a new solution in development that enables the computer-assisted marking of digital images of patients with AMD, the main cause of blindness in persons over 50, in developed countries.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.